C. Bohac

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
C Bohac, C. Bohac, Chet Bohac
Publication record
28 papers · 440 citations · H-index 11

PAPERS

659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
20221 citationsauthor #14
Abstract 330: Targeting B7-H3 in prostate cancer: Preclinical proof of concept with MGC018, an investigational anti-B7-H3 antibody-drug conjugate
20222 citationsauthor #10
620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
202124 citationsauthor #19
Abstract 1841: IMGC936, an investigational ADAM9-targeting antibody drug conjugate, is active against patient-derived ADAM9-expressing xenograft models
20210 citationsauthor #11
Abstract 950: Targeting B7-H3 in squamous cell carcinoma of the head and neck: Preclinical proof-of-concept with the investigational anti-B7-H3 antibody-drug conjugate, MGC018
20210 citationsauthor #10
926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
20212 citationsauthor #4
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States
202023 citationsauthor #10
Abstract 5203: MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3, exhibits immunomodulatory activity and enhanced antitumor activity in combination with checkpoint inhibitors
20205 citationsauthor #16
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
202024 citationsauthor #20
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
201972 citationsauthor #11
Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma.
20195 citationsauthor #6
Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy.
20181 citationsauthor #8
Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study
20185 citationsauthor #5
Systemic Anti-Cancer Therapy in Synovial Sarcoma: A Systematic Review
201848 citationsauthor #4
1480PDA phase 2 study of CMB305 and atezolizumab in NY-ESO-1+ soft tissue sarcoma: Interim analysis of immunogenicity, tumor control and survival
201714 citationsauthor #16
Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review
201780 citationsauthor #5
Associations between dermatologic toxicity severity, patient characteristics, and efficacy among patients treated with panitumumab (Pmab) and chemotherapy
20160 citationsauthor #4
Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
20163 citationsauthor #4
The effect of chemotherapy-induced anemia on dose reduction and dose delay
201621 citationsauthor #7
Patient and health care provider perceptions of cancer-related fatigue and pain
201659 citationsauthor #2
Safety and ef fi cacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer : a meta-analysis
20152 citationsauthor #9
Abstract P5-15-18: Hemoglobin levels and quality of life in patients with breast cancer and symptomatic chemotherapy-induced anemia enrolled in the eAQUA study
20150 citationsauthor #6
Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.
201528 citationsauthor #8
1509PADDITIONAL HAEMOGLOBIN (HB) AND QUALITY OF LIFE (QOL) ANALYSES FROM EAQUA.
20140 citationsauthor #9
Trends in Anemia Treatment Among Patients with Non-Myeloid Malignancies Treated with Chemotherapy
20140 citationsauthor #7
1508PHAEMOGLOBIN (HB) LEVELS AND QUALITY OF LIFE (QOL) IN PATIENTS (PTS) WITH SYMPTOMATIC CHEMOTHERAPY-INDUCED ANAEMIA (CIA): THE EAQUA STUDY.
20140 citationsauthor #9
The impact of fatigue and pain in elderly patients with cancer
20130 citationsauthor #3
Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
201221 citationsauthor #4

TIMELINE

2012 21 citations

2013 0 citations

2014 0 citations

2015 30 citations

2016 83 citations

2017 94 citations

2018 54 citations

2019 77 citations

2020 52 citations

2021 26 citations

2022 3 citations

C. Bohac

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT